Objectives Improvement of skin fibrosis is part of the natural course of diffuse cutaneous systemic sclerosis (dcSSc). Recognising those patients most likely to improve could help tailoring clinical management and cohort enrichment for clinical trials. In this study, we aimed to identify predictors for improvement of skin fibrosis in patients with dcSSc. Methods We performed a longitudinal analysis of the European Scleroderma Trials And Research (EUSTAR) registry including patients with dcSSc, fulfilling American College of Rheumatology criteria, baseline modified Rodnan skin score (mRSS) =7 and follow-up mRSS at 12 ±2 months. The primary outcome was skin improvement (decrease in mRSS of >5 points and =25%) at 1 year follow-up. A respective increase in mRSS was considered progression. Candidate predictors for skin improvement were selected by expert opinion and logistic regression with bootstrap validation was applied. Results From the 919 patients included, 218 (24%) improved and 95 (10%) progressed. Eleven candidate predictors for skin improvement were analysed. The final model identified high baseline mRSS and absence of tendon friction rubs as independent predictors of skin improvement. The baseline mRSS was the strongest predictor of skin improvement, independent of disease duration. An upper threshold between 18 and 25 performed best in enriching for progressors over regressors. Conclusions Patients with advanced skin fibrosis at baseline and absence of tendon friction rubs are more likely to regress in the next year than patients with milder skin fibrosis. These evidence-based data can be implemented in clinical trial design to minimise the inclusion of patients who would regress under standard of care.

Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis : A EUSTAR analysis / R. Dobrota, B. Maurer, N. Graf, S. Jordan, C. Mihai, O. Kowal-Bielecka, Y. Allanore, O. Distler, M.M. Cerinic, S. Guiducci, U. Walker, G. Lapadula, F. Iannone, R. Becvar, S. Sierakowsky, M. Cutolo, A. Sulli, G. Valentini, G. Cuomo, S. Vettori, G. Riemekasten, E. Siegert, S. Rednic, I. Nicoara, A. Kahan, P. Vlachoyiannopoulos, C. Montecucco, R. Caporali, P.E. Carreira, S. Novak, L. Czirják, C. Varju, C. Chizzolini, E.J. Kucharz, A. Kotulska, M. Kopec-Medrek, M. Widuchowska, F. Cozzi, B. Rozman, C. Mallia, B. Coleiro, A. Gabrielli, D. Farge, C. Wu, Z. Marjanovic, H. Faivre, D. Hij, R. Dhamadi, P. Airò, R. Hesselstrand, F. Wollheim, D.M. Wuttge, K. Andréasson, D. Martinovic, A. Balbir-Gurman, Y. Braun-Moscovici, F. Trotta, A.L. Monaco, N. Hunzelmann, R. Pellerito, O. Mauriziano, L.M. Bambara, P. Caramaschi, C. Black, C. Denton, N. Damjanov, J. Henes, V.O. Santamaria, S. Heitmann, D. Krasowska, M. Seidel, H. Burkhardt, A. Himsel, M.J. Salvador, J.A.P. Da Silva, B. Stamenkovic, A. Stankovic, M. Tikly, L.P. Ananieva, L.N. Denisov, U. Müller-Ladner, M. Frerix, I. Tarner, R. Scorza, M. Engelhart, G. Strauss, H. Nielsen, K. Damgaard, A.Z. Mendoza, C. de la Puente, W.A..S. Giraldo, Ø. Midtvedt, S. Reiseter, E. Hachulla, D. Launay, G. Valesini, V. Riccieri, R.M. Ionescu, D. Opris, L. Groseanu, R.S. Cornateanu, R. Ionitescu, A.M. Gherghe, A. Soare, M. Gorga, M. Bojinca, G. Schett, J.H.W. Distler, C. Beyer, P. Meroni, F. Ingegnoli, L. Mouthon, F.D. Keyser, V. Smith, F.P. Cantatore, A. Corrado, M.R. Pozzi, K. Eyerich, R. Hein, E. Knott, P. Wiland, M. Szmyrka-Kaczmarek, R. Sokolik, E. Morgiel, M. Madej, B. Krummel-Lorenz, P. Saar, M. Aringer, C. Günther, R. Westhovens, E. de Langhe, J. Lenaerts, B. Anic, M. Baresic, M. Mayer, S.C. Radominski, C. de Souza Müller, V.F. Azevedo, S. Agachi, L. Groppa, L. Chiaburu, E. Russu, S. Popa, T. Zenone, S. Stebbings, J. Highton, L. Stamp, P. Chapman, J. O'Donnell, K. Solanki, A. Doube, D. Veale, M. O'Rourke, E. Loyo, M. Li, E. Rosato, A. Amoroso, A. Gigante, C. Tanaseanu, M. Popescu, A. Dumitrascu, I. Tiglea, R. Foti, R. Chirieac, C. Ancuta, P. Villiger, S. Adler, P.G. de la Peña Lefebvre, S.R. Rubio, M.V. Exposito, J. Sibilia, E. Chatelus, J.E. Gottenberg, H. Chifflot, I. Litinsky, A. Venalis, I. Butrimiene, P. Venalis, R. Rugiene, D. Karpec, L.A. Saketkoo, J.A. Lasky, E. Kerzberg, F. Montoya, V. Cosentino, M. Limonta, A.L. Brucato, E. Lupi, F. Spertini, C. Ribi, G. Buss, J.L. Pasquali, T. Martin, A. Gorse. - In: ANNALS OF THE RHEUMATIC DISEASES. - ISSN 0003-4967. - 75:10(2016), pp. 1743-1748.

Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis : A EUSTAR analysis

R. Caporali;P. Meroni;F. Ingegnoli;A.L. Brucato;
2016

Abstract

Objectives Improvement of skin fibrosis is part of the natural course of diffuse cutaneous systemic sclerosis (dcSSc). Recognising those patients most likely to improve could help tailoring clinical management and cohort enrichment for clinical trials. In this study, we aimed to identify predictors for improvement of skin fibrosis in patients with dcSSc. Methods We performed a longitudinal analysis of the European Scleroderma Trials And Research (EUSTAR) registry including patients with dcSSc, fulfilling American College of Rheumatology criteria, baseline modified Rodnan skin score (mRSS) =7 and follow-up mRSS at 12 ±2 months. The primary outcome was skin improvement (decrease in mRSS of >5 points and =25%) at 1 year follow-up. A respective increase in mRSS was considered progression. Candidate predictors for skin improvement were selected by expert opinion and logistic regression with bootstrap validation was applied. Results From the 919 patients included, 218 (24%) improved and 95 (10%) progressed. Eleven candidate predictors for skin improvement were analysed. The final model identified high baseline mRSS and absence of tendon friction rubs as independent predictors of skin improvement. The baseline mRSS was the strongest predictor of skin improvement, independent of disease duration. An upper threshold between 18 and 25 performed best in enriching for progressors over regressors. Conclusions Patients with advanced skin fibrosis at baseline and absence of tendon friction rubs are more likely to regress in the next year than patients with milder skin fibrosis. These evidence-based data can be implemented in clinical trial design to minimise the inclusion of patients who would regress under standard of care.
epidemiology; outcomes research; systemic sclerosis; immunology and allergy; rheumatology; immunology; biochemistry, genetics and molecular biology (all)
Settore MED/16 - Reumatologia
2016
Article (author)
File in questo prodotto:
File Dimensione Formato  
Ann Rheum Dis-2016-Dobrota-1743-8.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 527.33 kB
Formato Adobe PDF
527.33 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/440911
Citazioni
  • ???jsp.display-item.citation.pmc??? 28
  • Scopus 66
  • ???jsp.display-item.citation.isi??? 63
social impact